Natura

Last updated January 31, 2026

275

Innovation Areas

20,463

Inventors

Collaborations

Anorectal mucosal adhesion formulations: NaturaRecent Research Landscape

Inconsistent bioavailability in inhaled delivery systems leads to unpredictable dosing and reduced efficacy. These innovations engineer the chemical matrix to stabilize active compounds for controlled pulmonary absorption.

What technical problems is Natura addressing in Anorectal mucosal adhesion formulations?

Inadequate mucosal residence time

(12)evidences

Inconsistent absorption and rapid degradation of therapeutic compounds at mucosal surfaces. Overcoming these barriers ensures effective localized delivery and sustained therapeutic concentrations.

Poor cannabinoid aqueous solubility

(8)evidences

Active compounds like cannabidiol often suffer from rapid clearance or low bioavailability at mucosal surfaces. Improving adhesion and solubility prevents premature expulsion and inconsistent therapeutic delivery.

Inadequate localized drug delivery

(7)evidences

Insufficient retention and absorption of therapeutic agents on mucosal surfaces. Improving delivery efficiency ensures consistent dosing and therapeutic efficacy in targeted tissues.